References

1. Wegovy® [summary of product characteristics]. Bagsværd,
   Denmark: Novo Nordisk A/S; 2024.
2. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide
   in patients with heart failure with preserved ejection fraction
   and obesity. N Engl J Med 2023;389(12):1069–1084.
3. Bliddal H, Bays H, Czernichow S, et al. Once-weekly
   semaglutide in persons with obesity and knee osteoarthritis.
   N Engl J Med. 2024;391(17):1573–1583. 
4. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of
   semaglutide in adults with overweight or obesity: the STEP 5
   trial. Nat Med. 2022;28(10):2083–2091.

HQ25SEMO00148
August 2025